Menu
Search Close

News

Appointment of Broker

06th September 2010

The Board of Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, announce the appointment of Matrix Corporate Capital LLP as joint broker with immediate effect.

For further information contact:

Professor Lindy Durrant - Scancell Holdings Plc

  • + 44 (0)207 245 1100

John Bick/Kirsty Corcoran - Hansard Communications

  • + 44 (0)207 245 1100

Ross Andrews/Tom Rowley - Zeus Capital - Nominated Adviser/Joint Broker

  • + 44 (0)161 831 1512

Robert Naylor/Stephen Waterman - Matrix Corporate Capital LLP - Joint Broker

  • +44 (0)20 3206 7340

View the full Document

Webcasts, Interviews and Media Coverage

Vulpes Life Sciences Fund's Martin Diggle discusses Scancell investment

Martin Diggle, co-founder of Vulpes Investment Management which manages the Vulpes Life Sciences Fund, discusses their recent investment into Scancell Holdings PLC (LON:SCLP).

After buying 77.56mln new shares at a price of 5p per share, which was a slight discount to the 5.35p closing price the previous day, the Vulpes Life Sciences Fund will have a 16.67% stake in the company.

Fri, 21 Jun 2019 08:21:00

Scancell welcomes strategic new investor Vulpes Life Sciences Fund

Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.

The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.

Thu, 13 Jun 2019 09:53:00

Scancell raises £3.9mln to advance immunotherapy product pipeline

“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”

Thu, 13 Jun 2019 06:31:00